» Articles » PMID: 30255612

Factors Influencing Survival After Recurrence in Osteosarcoma: A Report from the Children's Oncology Group

Overview
Date 2018 Sep 27
PMID 30255612
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Despite drastic improvement in overall survival for pediatric patients with cancer, those with osteosarcoma have stable rates of survival since the 1980s. This project evaluates the effect of several variables on survival after first recurrence in patients with osteosarcoma.

Methods: Data from three prospective North American cooperative group trials for newly diagnosed osteosarcoma are included: INT-0133, POG-9754, and AOST0121. The analytic population for this study is all enrolled patients with first event-free survival (EFS) event of relapse. The primary outcome measure for this retrospective analysis was survival after recurrence (SAR).

Results: The analytic population consisted of N = 431 patients. SAR was statistically significantly associated with age at enrollment (<10 years, P = 0.027), presence of metastatic disease at diagnosis (localized, P < 0.0001), site of relapse (combination lung + bone, unfavorable, P = 0.005), and time to first relapse (2+ years, favorable, P < 0.0001) in multivariate analysis. Ethnicity, primary site of tumor, race, and sex were not significantly related to SAR.

Conclusions: Prolonged SAR in patients with relapsed osteosarcoma is associated with age, extent of disease at diagnosis, site of and time to relapse. Adolescent and young adult patients with osteosarcoma have shorter SAR than younger patients, consistent with studies showing decreased overall survival in this group. Although patients with primary metastatic disease have shorter SAR, there is a subset of patients who relapse greater than 2 years from initial diagnosis that will become survivors. Histological response was significantly associated with time to relapse, but was not predictive of SAR.

Citing Articles

Prognostic factors for disease progression of central high-grade conventional osteosarcoma of the appendicular skeleton: Single-centre experience within South Africa with minimum 3-year follow-up.

Mthethwa P, Marais L J Orthop. 2025; 65():126-131.

PMID: 39867653 PMC: 11754155. DOI: 10.1016/j.jor.2024.12.019.


3D Tumor-Engineered Model Replicating the Osteosarcoma Stem Cell Niche and Tumor Complexity.

Bassi G, Rossi A, Campodoni E, Sandri M, Sarogni P, Fulle S ACS Appl Mater Interfaces. 2024; .

PMID: 39353598 PMC: 11492322. DOI: 10.1021/acsami.4c02567.


CAR T cells redirected to B7-H3 for pediatric solid tumors: Current status and future perspectives.

Epperly R, Gottschalk S, DeRenzo C EJC Paediatr Oncol. 2024; 3.

PMID: 38957786 PMC: 11218663. DOI: 10.1016/j.ejcped.2024.100160.


Solitary pulmonary metastases at first recurrence of osteosarcoma: Presentation, treatment, and survival of 219 patients of the Cooperative Osteosarcoma Study Group.

Mettmann V, Baumhoer D, Bielack S, Blattmann C, Friedel G, von Kalle T Cancer Med. 2023; 12(17):18219-18234.

PMID: 37548393 PMC: 10524021. DOI: 10.1002/cam4.6409.


Preclinical evaluation of Raman spectroscopy for pedicular screw insertion surgical guidance in a porcine spine model.

Kosik I, Dallaire F, Pires L, Tran T, Leblond F, Wilson B J Biomed Opt. 2023; 28(5):057003.

PMID: 37265877 PMC: 10231831. DOI: 10.1117/1.JBO.28.5.057003.


References
1.
Meyers P, Schwartz C, Krailo M, Healey J, Bernstein M, Betcher D . Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. J Clin Oncol. 2008; 26(4):633-8. DOI: 10.1200/JCO.2008.14.0095. View

2.
Gelderblom H, Jinks R, Sydes M, Bramwell V, Van Glabbeke M, Grimer R . Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials. Eur J Cancer. 2011; 47(6):895-902. DOI: 10.1016/j.ejca.2010.11.036. View

3.
Ferrari S, Briccoli A, Mercuri M, Bertoni F, Cesari M, Longhi A . Late relapse in osteosarcoma. J Pediatr Hematol Oncol. 2006; 28(7):418-22. DOI: 10.1097/01.mph.0000212944.82361.1d. View

4.
Harrison D, Geller D, Gill J, Lewis V, Gorlick R . Current and future therapeutic approaches for osteosarcoma. Expert Rev Anticancer Ther. 2017; 18(1):39-50. DOI: 10.1080/14737140.2018.1413939. View

5.
Lewis I, Nooij M, Whelan J, Sydes M, Grimer R, Hogendoorn P . Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst. 2007; 99(2):112-28. DOI: 10.1093/jnci/djk015. View